Modulating cancer cell survival by targeting intracellular cholesterol transport

Omer Kuzu, Raghavendra Gowda, Mohammad A. Noory, Gavin P. Robertson

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Demand for cholesterol is high in certain cancers making them potentially sensitive to therapeutic strategies targeting cellular cholesterol homoeostasis. A potential approach involves disruption of intracellular cholesterol transport, which occurs in Niemann-Pick disease as a result of acid sphingomyelinase (ASM) deficiency. Hence, a class of lysosomotropic compounds that were identified as functional ASM inhibitors (FIASMAs) might exhibit chemotherapeutic activity by disrupting cancer cell cholesterol homoeostasis.Methods: Here, the chemotherapeutic utility of ASM inhibition was investigated. The effect of FIASMAs on intracellular cholesterol levels, cholesterol homoeostasis, cellular endocytosis and signalling cascades were investigated. The in vivo efficacy of ASM inhibition was demonstrated using melanoma xenografts and a nanoparticle formulation was developed to overcome dose-limiting CNS-associated side effects of certain FIASMAs.Results: Functional ASM inhibitors inhibited intracellular cholesterol transport leading to disruption of autophagic flux, cellular endocytosis and receptor tyrosine kinase signalling. Consequently, major oncogenic signalling cascades on which cancer cells were reliant for survival were inhibited. Two tested ASM inhibitors, perphenazine and fluphenazine that are also clinically used as antipsychotics, were effective in inhibiting xenografted tumour growth. Nanoliposomal encapsulation of the perphenazine enhanced its chemotherapeutic efficacy while decreasing CNS-associated side effects.Conclusions: This study suggests that disruption of intracellular cholesterol transport by targeting ASM could be utilised as a potential chemotherapeutic approach for treating cancer.

Original languageEnglish
Pages (from-to)513-524
Number of pages12
JournalBritish Journal of Cancer
Volume117
Issue number4
DOIs
Publication statusPublished - 8 Aug 2017
Externally publishedYes

Fingerprint

Sphingomyelin Phosphodiesterase
Cell Survival
Cholesterol
Acids
Neoplasms
Perphenazine
Homeostasis
Endocytosis
Type A Niemann-Pick Disease
Niemann-Pick Diseases
Fluphenazine
Receptor Protein-Tyrosine Kinases
Heterografts
Nanoparticles
Antipsychotic Agents
Melanoma
Growth

Keywords

  • ASM inhibitors
  • autophagy
  • cholesterol transport inhibitors
  • functional acid sphingomyelinase inhibitors
  • lysosomotropism
  • melanoma
  • SMPD1

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Modulating cancer cell survival by targeting intracellular cholesterol transport. / Kuzu, Omer; Gowda, Raghavendra; Noory, Mohammad A.; Robertson, Gavin P.

In: British Journal of Cancer, Vol. 117, No. 4, 08.08.2017, p. 513-524.

Research output: Contribution to journalArticle

Kuzu, Omer ; Gowda, Raghavendra ; Noory, Mohammad A. ; Robertson, Gavin P. / Modulating cancer cell survival by targeting intracellular cholesterol transport. In: British Journal of Cancer. 2017 ; Vol. 117, No. 4. pp. 513-524.
@article{5a6dd4497712472fb33199f1c11d4400,
title = "Modulating cancer cell survival by targeting intracellular cholesterol transport",
abstract = "Background: Demand for cholesterol is high in certain cancers making them potentially sensitive to therapeutic strategies targeting cellular cholesterol homoeostasis. A potential approach involves disruption of intracellular cholesterol transport, which occurs in Niemann-Pick disease as a result of acid sphingomyelinase (ASM) deficiency. Hence, a class of lysosomotropic compounds that were identified as functional ASM inhibitors (FIASMAs) might exhibit chemotherapeutic activity by disrupting cancer cell cholesterol homoeostasis.Methods: Here, the chemotherapeutic utility of ASM inhibition was investigated. The effect of FIASMAs on intracellular cholesterol levels, cholesterol homoeostasis, cellular endocytosis and signalling cascades were investigated. The in vivo efficacy of ASM inhibition was demonstrated using melanoma xenografts and a nanoparticle formulation was developed to overcome dose-limiting CNS-associated side effects of certain FIASMAs.Results: Functional ASM inhibitors inhibited intracellular cholesterol transport leading to disruption of autophagic flux, cellular endocytosis and receptor tyrosine kinase signalling. Consequently, major oncogenic signalling cascades on which cancer cells were reliant for survival were inhibited. Two tested ASM inhibitors, perphenazine and fluphenazine that are also clinically used as antipsychotics, were effective in inhibiting xenografted tumour growth. Nanoliposomal encapsulation of the perphenazine enhanced its chemotherapeutic efficacy while decreasing CNS-associated side effects.Conclusions: This study suggests that disruption of intracellular cholesterol transport by targeting ASM could be utilised as a potential chemotherapeutic approach for treating cancer.",
keywords = "ASM inhibitors, autophagy, cholesterol transport inhibitors, functional acid sphingomyelinase inhibitors, lysosomotropism, melanoma, SMPD1",
author = "Omer Kuzu and Raghavendra Gowda and Noory, {Mohammad A.} and Robertson, {Gavin P.}",
year = "2017",
month = "8",
day = "8",
doi = "10.1038/bjc.2017.200",
language = "English",
volume = "117",
pages = "513--524",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Modulating cancer cell survival by targeting intracellular cholesterol transport

AU - Kuzu, Omer

AU - Gowda, Raghavendra

AU - Noory, Mohammad A.

AU - Robertson, Gavin P.

PY - 2017/8/8

Y1 - 2017/8/8

N2 - Background: Demand for cholesterol is high in certain cancers making them potentially sensitive to therapeutic strategies targeting cellular cholesterol homoeostasis. A potential approach involves disruption of intracellular cholesterol transport, which occurs in Niemann-Pick disease as a result of acid sphingomyelinase (ASM) deficiency. Hence, a class of lysosomotropic compounds that were identified as functional ASM inhibitors (FIASMAs) might exhibit chemotherapeutic activity by disrupting cancer cell cholesterol homoeostasis.Methods: Here, the chemotherapeutic utility of ASM inhibition was investigated. The effect of FIASMAs on intracellular cholesterol levels, cholesterol homoeostasis, cellular endocytosis and signalling cascades were investigated. The in vivo efficacy of ASM inhibition was demonstrated using melanoma xenografts and a nanoparticle formulation was developed to overcome dose-limiting CNS-associated side effects of certain FIASMAs.Results: Functional ASM inhibitors inhibited intracellular cholesterol transport leading to disruption of autophagic flux, cellular endocytosis and receptor tyrosine kinase signalling. Consequently, major oncogenic signalling cascades on which cancer cells were reliant for survival were inhibited. Two tested ASM inhibitors, perphenazine and fluphenazine that are also clinically used as antipsychotics, were effective in inhibiting xenografted tumour growth. Nanoliposomal encapsulation of the perphenazine enhanced its chemotherapeutic efficacy while decreasing CNS-associated side effects.Conclusions: This study suggests that disruption of intracellular cholesterol transport by targeting ASM could be utilised as a potential chemotherapeutic approach for treating cancer.

AB - Background: Demand for cholesterol is high in certain cancers making them potentially sensitive to therapeutic strategies targeting cellular cholesterol homoeostasis. A potential approach involves disruption of intracellular cholesterol transport, which occurs in Niemann-Pick disease as a result of acid sphingomyelinase (ASM) deficiency. Hence, a class of lysosomotropic compounds that were identified as functional ASM inhibitors (FIASMAs) might exhibit chemotherapeutic activity by disrupting cancer cell cholesterol homoeostasis.Methods: Here, the chemotherapeutic utility of ASM inhibition was investigated. The effect of FIASMAs on intracellular cholesterol levels, cholesterol homoeostasis, cellular endocytosis and signalling cascades were investigated. The in vivo efficacy of ASM inhibition was demonstrated using melanoma xenografts and a nanoparticle formulation was developed to overcome dose-limiting CNS-associated side effects of certain FIASMAs.Results: Functional ASM inhibitors inhibited intracellular cholesterol transport leading to disruption of autophagic flux, cellular endocytosis and receptor tyrosine kinase signalling. Consequently, major oncogenic signalling cascades on which cancer cells were reliant for survival were inhibited. Two tested ASM inhibitors, perphenazine and fluphenazine that are also clinically used as antipsychotics, were effective in inhibiting xenografted tumour growth. Nanoliposomal encapsulation of the perphenazine enhanced its chemotherapeutic efficacy while decreasing CNS-associated side effects.Conclusions: This study suggests that disruption of intracellular cholesterol transport by targeting ASM could be utilised as a potential chemotherapeutic approach for treating cancer.

KW - ASM inhibitors

KW - autophagy

KW - cholesterol transport inhibitors

KW - functional acid sphingomyelinase inhibitors

KW - lysosomotropism

KW - melanoma

KW - SMPD1

UR - http://www.scopus.com/inward/record.url?scp=85027013187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027013187&partnerID=8YFLogxK

U2 - 10.1038/bjc.2017.200

DO - 10.1038/bjc.2017.200

M3 - Article

VL - 117

SP - 513

EP - 524

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 4

ER -